miR-146a has been implicated in the regulation of the immune response as well as in inflammatory process of atherosclerosis. In the present study, we have investigated the expression of miR-146a and its targets, TLR4 a IRAK1, in aortic valve stenosis. A total of 58 patients with aortic stenosis (non- and atherosclerotic; tissue obtained during standard aortic valve replacement) were enrolled. The relative expression of mir-146a was higher in valvular tissue from patients with atherosclerosis compared to those without atherosclerosis (p = 0.01). Number of the IRAK1 and TLR4 transcripts did not differ between the investigated groups. There was a trend toward elevation of miR-146a expression in context of inflammatory infiltrate observed in the valvular tissue from patients with atherosclerosis (p = 0.06). In conclusion, in line with the acknowledged role of miR-146a in atherosclerotic inflammation, our data suggest it may be extended to the specific location of aortic valves in aortic stenosis.

Department of Cardiac Surgery Palacky University and University Hospital Olomouc Czechia

Department of Clinical and Molecular Pathology Faculty of Medicine and Dentistry Palacky University Olomouc Czechia

Department of Pathological Physiology Faculty of Medicine Dentistry Palacky University Olomouc Czechia

Faculty of Medicine and Dentistry Institute of Molecular and Translational Medicine Palacky University Olomouc Czechia

Internal Medicine 1 Cardiology Palacky University and University Hospital Olomouc Czechia

Laboratory of Cardiogenomics University Hospital Olomouc Olomouc Czechia

Zobrazit více v PubMed

Mohler ER. Are atherosclerotic processes involved in aortic-valve calcification? Lancet. (2000) 356:524–5. 10.1016/S0140-6736(00)02572-1 PubMed DOI

Thaden JJ, Nkomo VT, Enriquez-Sarano M. The global burden of aortic stenosis. Prog Cardiovasc Dis. (2014) 56:565–71. 10.1016/j.pcad.2014.02.006 PubMed DOI

Pasipoularides A. Calcific aortic valve disease: part 1—molecular pathogenetic aspects, hemodynamics, and adaptive feedbacks. J Cardiovasc Transl Res. (2016) 9:102–18. 10.1007/s12265-016-9679-z PubMed DOI PMC

Cho KI, Sakuma I, Sohn IS, Jo S-H, Koh KK. Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease. Atherosclerosis. (2018) 277:60–5. 10.1016/j.atherosclerosis.2018.08.029 PubMed DOI

Gošev I, Zeljko M, Durić Ž, Nikolić I, Gošev M, Ivčević S, et al. . Epigenome alterations in aortic valve stenosis and its related left ventricular hypertrophy. Clin Epigenet. (2017) 9:106. 10.1186/s13148-017-0406-7 PubMed DOI PMC

Menon V, Lincoln J. The genetic regulation of aortic valve development and calcific disease. Front Cardiovasc Med. (2018) 5:162. 10.3389/fcvm.2018.00162 PubMed DOI PMC

Kishore A, Petrek M. Next-generation sequencing based HLA typing: deciphering immunogenetic aspects of sarcoidosis. Front Genet. (2018) 9:503. 10.3389/fgene.2018.00503 PubMed DOI PMC

Kishore A, Borucka J, Petrkova J, Petrek M. Novel insights into miRNA in lung and heart inflammatory diseases. Mediators Inflamm. (2014) 2014:1–27. 10.1155/2014/259131 PubMed DOI PMC

Cheng HS, Besla R, Li A, Chen Z, Shikatani EA, Nazari-Jahantigh M, et al. . Paradoxical Suppression of atherosclerosis in the absence of microRNA-146a. Circ Res. (2017) 121:354–67. 10.1161/CIRCRESAHA.116.310529 PubMed DOI PMC

Nguyen M-A, Karunakaran D, Geoffrion M, Cheng HS, Tandoc K, Perisic Matic L, et al. . Extracellular vesicles secreted by atherogenic macrophages transfer MicroRNA to inhibit cell migration. Arterioscler Thromb Vasc Biol. (2018) 38:49–63. 10.1161/ATVBAHA.117.309795 PubMed DOI PMC

Taganov KD, Boldin MP, Chang K-J, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. (2006) 103:12481–6. 10.1073/pnas.0605298103 PubMed DOI PMC

Li S, Yue Y, Xu W, Xiong S. MicroRNA-146a represses Mycobacteria-induced inflammatory response and facilitates bacterial replication via targeting IRAK-1 and TRAF-6. PLoS ONE. (2013) 8:e81438. 10.1371/journal.pone.0081438 PubMed DOI PMC

Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. (2002) 105:1158–61. 10.1161/circ.105.10.1158 PubMed DOI

García-Rodríquez C, Parra-Izquierdo I, Castaños-Mollor I, López J, San Román JA, Sánchez Crespo M. Toll-like receptors, inflammation, and calcific aortic valve disease. Front Physiol. (2018) 9:201 10.3389/fphys.2018.00201 PubMed DOI PMC

Li J, Wan Y, Guo Q, Zou L, Zhang J, Fang Y, et al. . Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther. (2010) 12:R81. 10.1186/ar3006 PubMed DOI PMC

Raitoharju E, Lyytikäinen L-P, Levula M, Oksala N, Mennander A, Tarkka M, et al. . MiR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the tampere vascular study. Atherosclerosis. (2011) 219:211–7. 10.1016/j.atherosclerosis.2011.07.020 PubMed DOI

Nazari-Jahantigh M, Wei Y, Schober A. The role of microRNAs in arterial remodelling. Thromb Haemost. (2012) 107:611–8. 10.1160/TH11-12-0826 PubMed DOI

Takahashi Y, Satoh M, Minami Y, Tabuchi T, Itoh T, Nakamura M. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin–angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci. (2010) 119:395–405. 10.1042/CS20100003 PubMed DOI

Xia P, Fang X, Zhang Z-H, Huang Q, Yan K-X, Kang K-F, et al. . Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions. Immunol. Lett. (2012) 148:151–62. 10.1016/j.imlet.2012.09.004 PubMed DOI

Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, et al. . MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging. (2009) 1:402–11. 10.18632/aging.100042 PubMed DOI PMC

Noreen M, Shah MAA, Mall SM, Choudhary S, Hussain T, Ahmed I, et al. . TLR4 polymorphisms and disease susceptibility. Inflamm Res. (2012) 61:177–88. 10.1007/s00011-011-0427-1 PubMed DOI

Zhu J, Mohan C. Toll-like receptor signaling pathways—therapeutic opportunities. Mediators Inflamm. (2010) 2010:781235. 10.1155/2010/781235 PubMed DOI PMC

Gong J, Tong Y, Zhang H-M, Wang K, Hu T, Shan G, et al. . Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat. (2012) 33:254–63. 10.1002/humu.21641 PubMed DOI

Xiong X-D, Cho M, Cai X-P, Cheng J, Jing X, Cen J-M, et al. . A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression. Mutat Res. (2014) 761:15–20. 10.1016/j.mrfmmm.2014.01.001 PubMed DOI

He Y, Yang J, Kong D, Lin J, Xu C, Ren H, et al. . Association of miR-146a rs2910164 polymorphism with cardio-cerebrovascular diseases: a systematic review and meta-analysis. Gene. (2015) 565:171–9. 10.1016/j.gene.2015.04.020 PubMed DOI

Wang H, Shi J, Li B, Zhou Q, Kong X, Bei Y. MicroRNA expression signature in human calcific aortic valve disease. Biomed Res Int. (2017) 2017:4820275. 10.1155/2017/4820275 PubMed DOI PMC

Duan C, Cao Z, Tang F, Jian Z, Liang C, Liu H, et al. . miRNA-mRNA crosstalk in myocardial ischemia induced by calcified aortic valve stenosis. Aging. (2019) 11:448–66. 10.18632/aging.101751 PubMed DOI PMC

Blaser MC, Aikawa E. Roles and regulation of extracellular vesicles in cardiovascular ineral metabolism. Front Cardiovasc Med. (2018) 5:187. 10.3389/fcvm.2018.00187 PubMed DOI PMC